Increased de novo lipogenesis mediated by FASN facilitated gemcitabine resistance in pancreatic cancer22 while cancer-associated adipose tissue promoted resistance to antiangiogenic interventions by supplying FA to cancer cells in regions where the glucose demand was insufficient23. Here, FASN is linked to cancer.